INTRODUCTION
============

Obstructive sleep apnea (OSA) is a common sleep-related breathing disorder characterized by recurrent partial or complete obstruction of the upper airway leading to intermittent hypoxia and frequent arousals during sleep. Many studies have demonstrated that patients with OSA show a relatively higher prevalence of atherosclerotic cerebrovascular and cardiovascular diseases ([@B1][@B2][@B3][@B4][@B5]). A dentist or otolaryngologist uses a cephalometric radiograph to analyze the patient\'s craniofacial characteristics (retrognathic mandible, narrow palate, tonsillar hypertrophy, and macroglossia) to fabricate an oral appliance for OSA. In some cases, carotid arterial calcification (CarAC) may be identified ([@B6][@B7]). Tsuda et al. ([@B7]) reported that subjects showing calcification in the carotid artery area on a cephalometric radiograph have higher Framingham risk scores than those without calcification. They concluded that the presence of CarAC in patients with OSA indicates a cardiovascular risk. However, cephalometry provides a two-dimensional (2D) image; hence, it may be limited to only detecting calcification, as the quantitative analysis of calcification is unavailable. Notably, these authors did not assess the direct relationship between CarAC and the development of a real cardiovascular event. The Agatston\'s method (Agatston score) has been widely used to assess calcification of coronary arteries and predict cardiovascular events ([@B8][@B9][@B10][@B11]). Several investigators have reported the feasibility of this method by focusing on quantifying CarAC using a carotid computed tomography (CT) scan ([@B12][@B13][@B14]). Airway CT is commonly used to evaluate the three-dimensional (3D) airway morphology in patients with OSA to detect an anatomically obstructive site ([@B15]), and the carotid arteries are always included in the z-axis range of this CT scan. Therefore, we performed a quantitative analysis of CarAC using the airway CT scans of OSA patients using the Agatston method. The purpose of this study was to evaluate the clinical value of CarAC as a predictor of cerebrocardiovascular disease (CCVD) in OSA patients.

MATERIALS AND METHODS
=====================

Subjects
--------

In total, 408 consecutive patients undergoing both polysomnography (PSG) and upper airway CT from March 2011 to October 2015 at our medical center were enrolled. Patients \< 40 years (n = 104) or \> 80 years (n = 1), and those with an incomplete medical record or lost to follow-up during the clinical work-up period (n = 2) were excluded. Among the 301 subjects included, 14 patients with a history of cardiovascular or cerebrovascular disease (e.g., old myocardial infarction or old stroke) were excluded based on their medical records or direct interviews. Finally, 287 patients (224 males, 63 females; mean age 54.5 ± 8.2 years; age range 40--79 years) were enrolled in this study ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). The institutional ethics committee approved this study and written informed consent was waived.

Polysomnography
---------------

Patients were diagnosed with OSA based on an overnight PSG (Alice 5, 19 channels; Philips Respironics, Inc., Kennesaw, GA, USA). The PSG is a multi-parametric sleep test, used as a diagnostic tool for OSA, provides simultaneous recordings of multiple physiological parameters related to sleep and wakefulness and directly monitors and quantifies the number of respiratory events, such as obstructive, central, or complex, and the resulting hypoxemia and arousals related to respiratory events.

In this study, apnea was defined as a \> 90% reduction of airflow for at least 10 seconds, and hypopnea as ≥ 30% decrease in airflow for at least 10 seconds combined with an arousal and/or ≥ 4% oxygen desaturation. Respiratory effort related arousals (RERAs) were defined as increasing respiratory efforts for at least 10 seconds, followed by an abrupt arousal from deeper sleep, but did not meet the apnea or hypopnea criteria. The apnea-hypopnea index (AHI) is defined as the average number of apnea events plus hypopnea events per hour of sleep. The respiratory disturbance index (RDI) is the average number of combined apnea events, hypopnea events, and RERAs per hour during sleep (RDI = apnea + hypopnea + RERAs per hour of sleep). The RDI was used for severity classification and diagnosis of OSA. The severity of OSA was divided into four groups with respect to the RDI: normal (RDI \< 5), mild (RDI 5--14), moderate (RDI 15--29), and severe (RDI ≥ 30).

Measurement of Carotid Artery Calcification
-------------------------------------------

All subjects underwent non-contrast CT scans with a 320-detector-row scanner (Aquilion ONE; Canon Medical Systems Corporation, Otawara, Japan) for an airway evaluation within one week of the PSG examination. The CT scans were performed from the frontal sinus of the skull to the carina level of the distal trachea, to include both nasal and intra-thoracic airways ([Fig. 2A](#F2){ref-type="fig"}). The airway CT scan included the following parameters: collimation 320 × 0.5 mm, gantry rotation time 500 ms, tube voltage 120 kV tube voltage, tube current 80 mA, and slice thickness 0.5 mm. All datasets were processed with iterative reconstruction (AIDR 3D, Canon Medical Systems Corporation) with a 3-mm slice thickness and a 3-mm interval. The images were then transferred to commercial software (Vitrea 6.0; Vital Images, Minnetonka, MN, USA) for post-processing and analysis. The carotid arterial calcium scores (CarACS) were quantified using the modified Agatston method, as reported in previous studies ([@B11][@B13]). On axial CT images, the software automatically highlights densities \> 130 Hounsfield units in an area of 1 mm^3^ ([Fig. 2B](#F2){ref-type="fig"}). The evaluation of CarAC was performed by an experienced radiologist with particular attention to exclude bony spurs or calcified ligamentous structures, and sum of the calcium score was quantified automatically by the software. CarACS was measured in the common, external, and internal carotid arteries, and total CarACS was estimated as the sum of these scores.

Clinical Analysis
-----------------

The clinical histories of the subjects were reviewed retrospectively within one month of the CT study, which included the history of comorbid diseases (e.g., hypertension, diabetes mellitus, and smoking), lipid profile (total cholesterol, high-density lipoprotein \[HDL\] and low-density lipoprotein \[LDL\]), blood pressure, body weight/height, and body mass index (BMI). A history of CCVD of each subject was closely evaluated based on the medical record or direct interview for exclusion.

In this study, CCVD events were defined by the development of certain conditions after PSG and upper airway CT examinations, such as stroke, transient ischemic attack (TIA), myocardial infarction, unstable angina with significant coronary stenosis in patients undergoing coronary arterial intervention (coronary stent insertion or coronary arterial bypass graft surgery), and cerebrovascular or cardiovascular death (death caused by ischemic heart disease or stroke and sudden death). Stroke was defined as a focal neurological deficit lasting \> 24 hours with a clinically relevant lesion found on brain imaging without any non-vascular cause identified. TIA was defined as a focal neurological deficit lasting 30 seconds to 24 hours without the brain imaging suggesting stroke. The date of a CCVD event or date and cause of death were obtained by reviewing the hospital records. The follow-up period ranged from 31--80 months, and the mean follow-up period was 52.2 ± 16.0 (mean ± standard deviation) months.

Statistics
----------

The various clinical characteristics were compared among patients with and without CCVD events. The independent *t* test was used for continuous variables, and Fisher\'s exact test was used for binomial variables. The Mann-Whitney U-test was performed for non-normally distributed variables, according to the results produced by the Kolmogorov-Smirnov test. The CarACS was analyzed using logarithmic transformation after adding a constant of 1 to each score due to the wide range of values. Risk factors for outcomes were first examined using a univariate Cox proportional hazards model, and variables with a significant association (*p* \< 0.20) were applied to a multivariate Cox proportional hazards model. Cumulative incidence curves for CCVD events were estimated by the Kaplan-Meier method and evaluated by log-rank test. Statistical Package for Social Sciences (SPSS version 20.0; IBM Corp., Armonk, NY, USA) was used for all data analyses, and *p* values \< 0.05 were considered significant.

RESULTS
=======

Among the selected 287 patients, CCVD events occurred in 27 (9.3%) at the end of the follow-up period. One patient developed myocardial infarction and cerebral stroke simultaneously, 13 patients had a cardiovascular event, and the remaining 13 developed cerebrovascular events. The details of subjects with CCVD events have been summarized in [Table 2](#T2){ref-type="table"}.

The CCVD event-present (+) group showed a significantly higher mean age than the CCVD event-absent (−) group (57.5 ± 7.7 vs. 54.2 ± 8.2, *p* = 0.047). The total number of patients with hypertension was 104 among the 287 subjects (36.4%), and the prevalence of hypertension was significantly higher in the CCVD event (+) group than the CCVD event (−) group (59.3% \[16/27\] vs. 34.0% \[88/260\], *p* = 0.017). Sex, lipid profiles (total cholesterol, HDL, and LDL), BMI, smoking history, and RDI were not different between the CCVD events (+) and CCVD events (−) groups ([Table 3](#T3){ref-type="table"}).

The PSG results of the subjects are summarized in [Table 4](#T4){ref-type="table"}. The mean AHI, RERA, Epworth Sleepiness Scale, and lowest O~2~ saturation were not different between the two groups. OSA severity was divided into four groups (normal, mild, moderate, and severe) using RDI, and the numbers of subjects in each group were, normal OSA = 39; mild OSA = 42; moderate OSA = 74; and severe OSA = 132.

Mild, moderate, and severe OSA groups showed similar percentages of CCVD events occurrence (5/42 \[11.9%\], 8/74 \[10.8%\], and 14/132 \[10.6%\], respectively), while the normal group reported no such events (0/39). However, the proportions of each number of patients according to severity of OSA were not significantly different between the CCVD event (+) group and CCVD event (−) group. CarAC was found in 68 patients (23.7%, 68/287), mean CarACS was 32.6 ± 129.6, and the mean log transformed calcium score \["Log(CarACS+1)"\] was 0.386 ± 0.774. The CCVD event (+) group showed significantly larger Log(CarACS+1) than the CCVD event (−) group (0.819 ± 0.979 vs. 0.341 ± 0.737, *p* = 0.002) ([Table 5](#T5){ref-type="table"}). The incidence of CarAC was 51.9% (14/27) in patients with CCVD events, which was significantly higher than in those with no CCVD events (20.8%, 54/260, *p* \< 0.001).

A univariate analysis using the Cox hazards model showed that age (odds ratio \[OR\], 1.047; *p* = 0.050), hypertension (OR, 2.826; *p* = 0.012), presence of CarAC (OR, 4.108; *p* \< 0.001), and log transformed CarACS (OR, 1.824; *p* = 0.004) were risk factors for CCVD events ([Table 6](#T6){ref-type="table"}). In the multivariate analysis, the presence of CarAC was the only independent risk factor for CCVD events (OR, 3.692; 95% confidence interval, 1.382--9.865: *p* = 0.009). The result of Kaplan-Meier analysis comparing the cumulative incidence curve according to the presence or absence of CarAC showed a significant difference (Log-rank test, *p* = 0.001) ([Fig. 3](#F3){ref-type="fig"}).

DISCUSSION
==========

OSA is a common disorder that is potentially harmful to health with immediate effects including intermittent hypoxia, fragmented sleep, and substantial influences on blood pressure and intrathoracic pressure, leading to hypertension, cardiovascular events, stroke, depression, and impaired quality of life ([@B1][@B2][@B3][@B4][@B5][@B16][@B17][@B18][@B19]). The OSA prevalence rate has increased substantially according to an American study reported in 2013, and the current prevalence estimates of moderate to severe OSA (AHI ≥ 15) are 10%, 17%, 3%, and 9% in 30--49-year-old males, 50--70-year-old males, 30--49-year-old females, and 50--70-year-old females, respectively ([@B20]). Although there is some debate about the effect of OSA treatment on the development of cardiovascular or cerebral events, many patients with OSA visit sleep apnea clinics for management and obtaining counseling for nasal continuous positive airway pressure (CPAP), which is the first-line OSA therapy ([@B21][@B22][@B23]). Therefore, physicians (dentists or otolaryngologists) in a sleep clinic may be concerned not only about managing the airway, but also about the management or consultation planning of comorbid diseases. Recently, airway CT has often been used to evaluate the 3D airway morphology in OSA patients before planning the treatment or during the follow-up period ([@B15][@B24][@B25][@B26]). The use of lateral cephalometric radiographs is limited, as it only provides 2D images of the airway. However, CT scans provide a detailed analysis of the relationship between the upper airway and its surrounding soft tissues (such as pharyngeal size at various levels of nasopharynx, oropharynx, and hypopharynx in patients with different dentofacial skeletal pattern), and dimensional analysis of the soft palate and tongue to determine the linear, volumetric, and cross-sectional area measurements for evaluation of the interaction of upper airway size and dentofacial structures. In the same manner, airway CT is routinely used in sleep clinics simultaneously with PSG in OSA patients. Therefore, we could analyze the CarACS retrospectively without additional radiation exposure.

In our study, the incidence of CCVD events in OSA patients was 9.3% at the end of follow-up, with similar incidences of cardiovascular and cerebrovascular events (4.9%). These incidence rates were consistent or slightly lower than prior studies: Gottlieb et al. ([@B1]) reported a 10.6% (473/4422) incidence of coronary heart disease, and Munoz et al. ([@B4]) reported 5.1% (20/394) incidence of ischemic stroke. We speculated that the causes of this incidence difference of CCVD were the relatively short follow-up period of our study and the data from a single medical center, which might have underestimated the CCVD events. Although the CCVD events were not evaluated in non-OSA subjects in this study, a recent retrospective population-based follow up study reported that one cohort had a 1.95-fold higher incidence of major adverse cardiac events compared to a non-OSA cohort ([@B27]). Various mechanisms have been reported regarding the relationship between OSA and vascular disease ([@B20][@B28][@B29][@B30]). One review article suggested three possible biological mechanisms supporting the association between OSA, endothelial dysfunction, and arterial disease: intermittent hypoxia leading to increased oxidative stress, systemic inflammation, and sympathetic activity; changes in intrathoracic pressure leading to excessive mechanical stress on the heart and large artery walls; and arousal-induced reflex sympathetic activation with consequent repetitive rises in blood pressure ([@B30]).

Majority of the previous studies have used panoramic dental radiographs to evaluate CarAC and its prevalence in the general dental population was 0.8--9% ([@B31][@B32][@B33]). Tsuda et al. ([@B6]) evaluated the CarAC prevalence in cephalometric radiographs among OSA patients and detected a higher prevalence of CarAC than the general population (9.5% vs. 6.7%). To the best of our knowledge, this is the first study that investigates CarAC in OSA patients using CT, and the prevalence of CarAC was relatively higher than that reported by prior studies (23.7%). This was probably because of the use of CT with higher detectability of calcification than the radiographic images, and the difference in the inclusion criteria for the study population (subjects ≥ 40).

Several investigators have reported that the presence of CarAC is an important marker of vascular risk. Cohen et al. ([@B34]) reported that 34% of patients with CarAC on a panoramic radiograph suffered cardiovascular or cerebrovascular events. Moreover, Friedlander et al. ([@B35]) evaluated the prevalence of CarAC on panoramic radiographs of recent stroke patients, and found its presence in 37% of subjects. In a population-based study, a positive correlation was detected between CarAC and CarACS estimated by CT images ([@B36]). The CarACS is an accepted method to evaluate coronary heart disease risk and is a subclinical atherosclerosis marker for the prediction of future cardiovascular events ([@B9][@B10][@B11]). The prognostic value of CarACS for incident stroke remains controversial; however, according to recently published meta-analysis study, despite the low the incidence of stroke (0.26 %/year), the presence of coronary calcification predicts approximately three times higher likelihood for incident stroke as compared to absence of calcifications ([@B37][@B38][@B39][@B40]). Based on this, we speculated that CarAC might also be associated with cardiovascular events, besides cerebral accidents.

In our study, the prevalence of CarAC (CarACS \> 0) was 51.9% (14/27) in patients with CCVD events, which was significantly higher than in patients without CCVD events. However, only 40.7% (11/27) of patients had CarACS \> 10. We speculated that the main cause of relatively low CarACS in the majority of patients with CCVD events could be the relatively young age of patients (among 27 patients, 17 were \< 60 years). Some studies reported that in comparison to their age-matched population, younger people with OSA had a higher risk of CCVD than the older ([@B41][@B42]). On the other hand, several studies reported that the non-calcified plaque showed higher vulnerability to develop cerebral or myocardial infarction than calcified plaques. Moreover, some investigators suggested that calcified portions of plaques are in a relatively stable state and seldom rupture ([@B43]). Our study adopted a non-contrast CT scan protocol for the evaluation of the upper airway; therefore, we could not evaluate the luminal status or plaque characteristics of the carotid arteries.

We found that the CCVD events were associated with CarAC/CarACS in addition to conventional risk factors (age and hypertension) in OSA patients. However, OSA severity did not contribute significantly to CCVD events. OSA has been considered as a risk factor for CCVD events; however, it remains unclear whether OSA is an independent or accelerating factor (coexisting with other atherogenic risk factors) for increased CCVD risk ([@B1][@B2][@B3][@B4][@B5]). In our study, the presence of OSA was associated with a higher risk of CCVD, but the severity of OSA did not significantly contribute to CCVD events. The direct relationship between the severity of OSA and the development of CCVD is debatable; however, the association of severe untreated OSA with diminished probability of long-term survival has been confirmed in large-cohort population-based studies ([@B44][@B45]). Since the number of subjects in each severity group was uneven and relatively small in our study, we could not control the baseline characteristics of each group. Thus, we speculated that the conventional atherogenic risk factors, such as age or hypertension frequently coexisting in the population with OSA, could have more influence on CCVD events than the OSA severity. Furthermore, the disease duration or treatment status of OSA and the medication for other comorbid diseases may contribute to the potential long-term risk of CCVD.

The association between CarAC and CCVD events persisted even after the traditional atherogenic risk parameters were adjusted, whereas the effect of age, hypertension, and CarACS disappeared. Arterial calcification occurs during the atherosclerotic process, thus, CarAC may potentially reflect all associated parameters for CCVD development. Therefore, in our study, CarAC was an independent risk factor for CCVD events in OSA patients. These results will be important for managing comorbid risk factors for atherosclerosis to prevent CCVD in OSA patients, and to treat OSA in sleep clinics effectively.

There were several limitations of in our study. First, the number of subjects was relatively small and the proportion of patients in each OSA severity category was uneven, which might have affected the statistical results. Second, females were underrepresented in this study with lower prevalence of OSA. It has long been recognized that males have greater vulnerability than females towards developing OSA. Clinic-based studies have shown that in patients referred for clinical evaluation, the ratio of male to female ranged from 5 to 8:1 ([@B46][@B47]). We consecutively included all the OSA patients who had visited our sleep clinic without any exclusion for the female sex, and the sex proportion of our subjects was consistent with previously reported studies. Third, the follow-up period for CCVD events was relatively short and differed among the subjects. Lastly, CPAP and other treatments for OSA or comorbid diseases were not taken into consideration.

In conclusion, the CarAC was an independent risk factor in the occurrence of CCVD events in OSA patients, whereas the RDI did not contribute as a risk factor. This study suggests that additional analyses of CarACS on airway CT in OSA patients may provide information for successful prediction of CCVD.
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![Patient flow diagram.\
Total of 408 patients who had undergone PSG and upper airway CT scan and 303 patients aged 40--80 years were included. Sixteen patients were excluded due to incomplete data or history of cardiovascular or cerebrovascular event, and 287 patients were included as final subjects. CT = computed tomography, PSG = polysomnography](kjr-20-631-g001){#F1}

![Representative images of airway CT scans.\
**(A)** CT scans starts from frontal sinus of skull ('FS') to carina level of distal trachea ('C'), including both upper airway and trachea; **(B)** Semi-automatic measurement of CarAC for calculating Agatston score; software automatically highlights calcification (coding to yellow color) with CT number higher than 130 Hounsfield units. Following this, reader determines carotid arterial calcium (arrow) based on anatomical information on each of CT images, and sum of calcium score is automatically quantified using software. CarAC = carotid arterial calcification](kjr-20-631-g002){#F2}

![Kaplan-Meier analysis of cerebrocardiovascular disease events of 287 patients according to presence or absence of CarAC (CarACS).\
Comparison between incidence curve proved to be significant (Log-rank test, *p* = 0.001). CarACS = carotid arterial calcium score](kjr-20-631-g003){#F3}

###### Characteristics of Enrolled Subjects

![](kjr-20-631-i001)

  ------------------------------ ---------------
  No. of patients                287
  Age (years)                    54.5 ± 8.2
  Male sex (%)                   224 (78.0)
  BMI (kg/m^2^)                  26.8 ± 4.7
  Smoking (%)                    
   Current                       61 (21.0)
   Past                          73 (25.5)
   Never                         153 (53.5)
  Hypertension^\*^               104 (36.4)
  Systolic BP                    130.2 ± 16.0
  Diastolic BP                   78.8 ± 12.9
  Diabetes mellitus^†^ (%)       36 (12.6)
  Total cholesterol (mg/dL)      191.5 ± 44.7
   HDL cholesterol (mg/dL)       50.5 ± 12.3
   LDL cholesterol (mg/dL)       114.4 ± 36.1
  RDI (event/h)                  30.6 ± 23.2
  AHI (event/h)                  27.4 ± 22.7
  RERAs (event/h)                3.9 ± 5.1
  ESS                            9.6 ± 4.6
  Lowest O~2~ saturation (%)     81.5 ± 9.8
  OSA groups (%)                 
   Normal (RDI \< 5)             41 (14.3)
   Mild (5 ≤ RDI \< 15)          42 (14.6)
   Moderate (15 ≤ RDI \< 30)     74 (25.8)
   Severe (30 ≤ RDI)             130 (45.3)
  Carotid artery calcification   68 (23.7)
  CarACS                         32.6 ± 129.6
  Log(CarACS+1)                  0.386 ± 0.774
  CarACS groups (%)              
   0--10                         235 (81.9)
   11--100                       34 (11.8)
   101--400                      11 (3.8)
   \> 400                        7 (2.4)
  ------------------------------ ---------------

Data are expressed as mean ± standard deviation or numbers of patients (%). ^\*^Patients were considered to have hypertension if their BP was persistently \> 140/90 mm Hg or if they were currently taking antihypertensive medication, ^†^Patients were considered to have diabetes mellitus if their fasting glucose level was ≥ 126 mg/dL, as assessed at least once, or if they were currently taking oral hypoglycemic agents or insulin. AHI = apnea-hypopnea index, BMI = body mass index, BP = blood pressure, CarACS = carotid arterial calcium score, ESS = Epworth Sleepiness Scale, HDL = high-density lipoprotein, LDL = low-density lipoprotein, OSA = obstructive sleep apnea, RDI = respiratory disturbance index, RERAs = respiratory effort related arousals

###### Subjects with CCVD Events
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  Subjects   CCVD Events                  CarACS   RDI
  ---------- ---------------------------- -------- ------
  M/73       UA (1-vessel, stent)         471.86   57.4
  M/70       Stroke (Lt. MCA)             283.59   32.9
  M/68       UA (2-vessel, stent)         37.46    19.6
  M/66       Stroke (Rt. PICA)            75.01    33.5
  F/66       Stroke (medullar)            0.00     18.3
  M/65       UA (2-vessel, stent)         39.29    46.0
  F/63       Stroke (Rt. MCA)             0.73     28.6
  F/63       Stroke (Rt. MCA)             3.12     24.5
  M/62       MI (1-vessel, stent), TIA    594.86   18.8
  F/62       Stroke (Lt. basal ganglia)   0.00     55.8
  M/59       TIA (Rt. lacunar)            0.00     21.4
  M/59       UA (1-vessel, stent)         7.20     37.8
  M/58       MI (1-vessel, CABG)          135.79   12.7
  M/57       UA (1-vessel, stent)         12.20    13.2
  M/55       UA (1-vessel, stent)         18.01    52.2
  F/55       TIA (vertebral artery)       0.00     36.9
  F/54       UA (1-vessel, stent)         0.00     48.7
  M/53       UA (1-vessel, stent)         0.00     38.3
  M/53       Stroke (cerebellum)          0.00     5.7
  M/52       Stroke (Lt. MCA)             0.00     31.1
  M/52       UA (2-vessel, stent)         28.35    11.3
  M/50       Stroke (medullar)            0.00     21.5
  M/50       Stroke (medullar)            0.00     29.1
  M/49       UA (1-vessel, stent)         0.00     84.2
  M/49       UA (3-vessel, CABG)          49.5     35.0
  M/46       Stroke (medullar)            0.00     71.9
  M/43       UA (1-vessel, stent)         0.00     7.0

CABG = coronary arterial bypass graft, CCVD = cerebrocardiovascular disease, F = female, Lt. = left, M = male, MCA = middle cerebral artery, MI = myocardial infarction, PICA = posterior inferior cerebellar artery, Rt. = right, TIA = transient ischemic attack, UA = unstable angina

###### Baseline Characteristics of Subjects with and without CCVD Events
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  Variables                   CCVD Event Absence   CCVD Event Presence   *P*
  --------------------------- -------------------- --------------------- -------
  No. of patient              260                  27                    
  Age (years)                 54.2 ± 8.2           57.5 ± 7.7            0.047
  Male sex (%)                203 (78.1)           21 (77.8)             1.000
  BMI (kg/m^2^)               26.8 ± 4.8           26.8 ± 3.3            0.979
  Smoking (%)                                                            0.290
   Current                    54 (20.8)            6 (22.2)              
   Past                       63 (24.3)            10 (37.0)             
   Never                      142 (54.8)           11 (40.7)             
  Hypertension^\*^            88 (34.0)            16 (59.3)             0.017
  Systolic BP                 130.5 ± 16.1         126.7 ± 15.6          0.246
  Diastolic BP                79.3 ± 12.9          74.4 ± 12.1           0.068
  Diabetes mellitus^†^ (%)    31 (12.0)            5 (18.5)              0.507
  Total cholesterol (mg/dL)   193.1 ± 44.9         180.4 ± 33.4          0.238
   HDL cholesterol (mg/dL)    50.8 ± 12.2          48.9 ± 13.3           0.574
   LDL cholesterol (mg/dL)    115.7 ± 37.0         108.5 ± 32.2          0.459

Data are expressed as mean ± standard deviation or numbers of patients (%). ^\*^Patients were considered to have hypertension if their BP was persistently \> 140/90 mm Hg or if they were currently taking antihypertensive medication, ^†^Patients were considered to have diabetes mellitus if their fasting glucose level was ≥ 126 mg/dL, as assessed at least once, or if they were currently taking oral hypoglycemic agents or insulin.

###### Polysomnographic Results of Subjects with and without CCVD Events
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  Variables                    CCVD Event Absence   CCVD Event Presence   *P*
  ---------------------------- -------------------- --------------------- -------
  No. of patient               260                  27                    
  RDI (event/h)                34.3 ± 22.5          33.1 ± 19.4           0.566
  AHI (event/h)                30.7 ± 22.4          29.4 ± 19.2           0.591
  RERAs (event/h)              3.9 ± 5.1            3.4 ± 4.9             0.750
  ESS                          9.6 ± 4.6            9.6 ± 4.7             0.927
  Lowest O~2~ saturation (%)   81.3 ± 10.0          83.1 ± 8.5            0.322
  OSA groups (%)                                                          0.191
   Normal (RDI \< 5)           39 (15.0)            0 (0)                 
   Mild (5 ≤ RDI \< 15)        37 (14.2)            5 (18.5)              
   Moderate (15 ≤ RDI \< 30)   66 (25.4)            8 (29.6)              
   Severe (30 ≤ RDI)           118 (45.4)           14 (51.8)             

Data are expressed as mean ± standard deviation or numbers of patients (%).

###### CarACS of Subjects with and without CCVD Events
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  Variables           CCVD Event Absence   CCVD Event Presence   *P*
  ------------------- -------------------- --------------------- ----------
  No. of patient      260                  27                    
  CarAC (%)           54 (20.8)            14 (51.9)             \< 0.001
  CarACS              29.2 ± 127.3         65.0 ± 148.5          0.173
  Log(CarACS+1)       0.341 ± 0.737        0.819 ± 0.979         0.002
  CarACS groups (%)                                              0.013
   0--10              219 (84.2)           16 (59.3)             
   11--100            27 (10.4)            7 (25.9)              
   101--400           9 (3.5)              2 (7.4)               
   \> 400             5 (1.9)              2 (7.4)               

Data are expressed as mean ± standard deviation or numbers of patients (%). CarAC: carotid arterial calcification

###### Risk Factors for CCVD Events by Cox Analysis
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  Variable            Univariate   Multivariate^\*^                                     
  ------------------- ------------ ------------------ ---------- ------- -------------- -------
  Age (years)         1.047        1.001--1.097       0.050      1.014   0.958--1.074   0.630
  Male                1.018        0.392--2.641       0.971                             
  BMI (kg/m^2^)       0.999        0.916--1.090       0.984                             
  Smoking             2.049        0.828--5.072       0.121                             
  Hypertension        2.826        1.258--6.351       0.012      2.021   0.840--4.860   0.116
  Diabetes mellitus   1.664        0.588--4.713       0.338                             
  Total cholesterol   0.993        0.943--1.002       0.235                             
  RDI (event/h)       0.995        0.977--1.013       0.565                             
  CarAC               4.108        1.824--9.255       \< 0.001   3.692   1.382--9.865   0.009
  Log(CarACS+1)       1.824        1.215--2.737       0.004      1.494   0.910--2.455   0.113

^\*^Multivariate model includes variables for which *p* \< 0.20 by univariate analysis. CI: confidence interval, OR: odds ratio

[^1]: ^\*^These authors contributed equally to this work.
